Could the secret to cheaper flights and fatter airline profits be... a slimmer you? It sounds like a plot twist, but the booming popularity of weight-loss drugs like Wegovy and Mounjaro might just be offering an unexpected financial boost to the airline industry. Imagine a world where your travel costs are subtly influenced by the nation's waistline – that's the intriguing possibility being explored by financial analysts.
But here's where it gets controversial... While many see these drugs as a personal health victory, a new perspective suggests they could have a ripple effect on the skies above. Analysts from the Wall Street investment bank Jefferies have crunched the numbers, and their findings are quite remarkable. They've calculated that if weight-loss trends continue, a society that's 10% slimmer could translate to an average 4% increase in earnings per share for major US airlines. That's a significant chunk of change!
Equities analyst Sheila Kahyaoglu of Jefferies succinctly put it: "A slimmer society = lower fuel consumption." This makes intuitive sense, as fuel is a substantial cost for airlines, typically accounting for 20-30% of their total expenses, which, of course, impacts the price of your ticket. Since 2022, the US adult obesity rate has seen a slight dip, moving from approximately 40% down to 37%, a shift partly attributed to the influence of GLP-1 drugs that regulate appetite and blood sugar.
Kahyaoglu further noted that with these drugs now available in pill form and obesity rates declining, their broader adoption could have even more pronounced effects on people's weight. She highlights that before the advent of GLP-1s, passenger weight was a factor largely beyond individual control. And this is the part most people miss... the cumulative effect of millions of people shedding pounds could have a tangible impact on the weight of aircraft.
Jefferies' team specifically looked at major US carriers like American, Delta, United, and Southwest. Their modeling suggests that a 10% slimmer US population would represent a 2% overall weight saving for these airlines. This reduction in weight could trim fuel expenses by as much as 1.5%, ultimately boosting earnings per share by an average of 3.9% across these four airlines. To put this into perspective, aviation company Honeywell estimates that every 450 grams (about one pound) of an aircraft's weight – encompassing crew, passengers, baggage, and the plane itself – can cost approximately $US10,000 (around $14,436 AUD) annually in fuel for commercial aircraft.
However, not everyone is convinced this will be a game-changer in the short term. Peter Harbison, Chairman of GreenerAirlines.com, suggests that while the initial rollout of GLP-1 drugs did spark expectations of increased travel demand from formerly obese customers, the impact on aircraft weight might be more subtle. He points out that airlines have already accounted for heavier passenger weights for years. "I think the drug’s impact would be marginal for the weight of aircraft in the short-to-medium term, given there are so many other variables," Harbison stated. "But if you were getting up to 1 per cent of the cost of the flight, it makes a difference."
In Australia, the obesity rate in 2022 was around 32%, according to the ABS, with reported drug usage also lower than in the US. As of 2025, only about 2% of Australians are estimated to be taking Ozempic and similar GLP-1 drugs, with a significant portion of these purchased privately. Salim Hijazeen, from Swinburne University's School of Engineering department of aviation, also expressed caution, suggesting that GLP-1s might only contribute a minor difference. He believes airlines are more likely to focus on direct fuel optimization strategies rather than relying on potential shifts in population health trends. "It’s very unlikely that something like this could significantly impact the weight of the aircraft in terms of the passenger weight," he commented.
To arrive at their forecast, Jefferies' analyst Kahyaoglu used a Boeing 737 Max 8 as a model. She calculated the weight of 178 passengers, assuming an average pre-Ozempic weight of 180 pounds (81.6 kg). After factoring in the estimated impact of the drug, the same group of passengers was calculated to weigh 178 pounds (80.7 kilos). This resulted in a difference of 3204 pounds in the aircraft's maximum take-off weight. Applying a widely used industry guideline where a 1% weight saving leads to a 0.75% improvement in fuel efficiency, a 2% improvement in aircraft weight could indeed translate to roughly 4% higher earnings per share, as Kahyaoglu's calculations suggest.
Harbison also recalled the early speculation surrounding Ozempic, where it was anticipated that individuals who lost weight would feel more confident about traveling. "The implication being that presumably even though they’ve lost a bit of weight they’re still above average, thereby presumably pushing up the average [on planes]," he mused. So, what do you think? Are weight-loss drugs a genuine factor in the future of air travel economics, or is this a case of overthinking a personal health trend? Let us know your thoughts in the comments below – we'd love to hear if you agree or disagree with this fascinating new perspective!
